Developer docs
API playgroundTry for free, no card

Search company profiles

Navega Therapeutics

Full company profile

uuid0000cye

Namestring
Navega Therapeutics
Legal namestring
Navega Therapeutics
Websiteurl
navegatx.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Navega Therapeutics is a preclinical-stage biotechnology company developing next-generation AAV gene therapies that use zinc-finger and CRISPR-based epigenome regulation to precisely control gene expression without permanently editing DNA. The company's lead candidate, NT-Z001, is an AAV gene therapy targeting the SCN9A gene encoding the NaV1.7 sodium channel, a well-validated pathway in pain transmission, with the goal of treating intractable chronic pain as a non-opioid, long-lasting alternative to existing therapies. The platform is described as broadly applicable to neurological and ophthalmic diseases, positioning NT-Z001 as the first of a potentially broader pipeline.

The company operates from JLABS San Diego (3210 Merryfield Row, San Diego, CA), a Johnson & Johnson biotech incubator, with a 1–10 person team led by founder and CEO Ana Moreno and co-founder, President and CSO Fernando Aleman, supported by CBO Carol Greve-Philips. Navega is privately held, founded in 2018, and has been funded entirely through non-dilutive federal grants rather than venture capital — receiving approximately $11.85 million cumulatively from the National Cancer Institute, the National Institute of Neurological Disorders and Stroke, and the California Institute for Regenerative Medicine (CIRM), including a $4 million Translational Science grant awarded in February 2025.

The business model is pre-commercial: Navega has no products on market, no pricing structure, and no paying customers. Revenue mechanics are entirely grant-based at present, with future value expected to derive from out-licensing, partnership, or commercialization of gene-therapy assets following regulatory approval. Distribution would occur via clinical-trial sites and specialty healthcare channels post-approval. Go-to-market is therefore not yet defined, and the company's near-term milestones are scientific and regulatory (preclinical → IND-enabling → clinical) rather than commercial.

Short descriptiontext

Navega Therapeutics is a preclinical San Diego biotech developing AAV gene therapies that use zinc-finger and CRISPR-based epigenome regulation to treat intractable chronic pain, with lead candidate NT-Z001 targeting the SCN9A/NaV1.7 sodium channel pathway.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
gene therapy development, epigenetic therapeutics, chronic pain treatment, AAV gene therapy, neurological disease therapy
Industry3 codes
PRIMARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAD
Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Gene Therapy
Social media profiles1 record
Revenue model1 record
1Pre-commercial / Pipeline Stage
TypeOne Time License
Description

Company is in preclinical development stage with no commercial products. Future revenue expected from gene therapy product commercialization, licensing deals, and potential partnership structures typical of biotech development pipelines.

navegatx.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Navega Therapeutics is a preclinical-stage biotechnology company developing next-generation AAV gene therapies for neurological and ophthalmic diseases by harnessing zinc-finger and CRISPR-based epigenome regulation to control gene expression. Its lead candidate NT-Z001 targets the SCN9A gene encoding the NaV1.7 sodium channel to treat intractable chronic pain as a potential non-opioid alternative.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Navega Therapeutics is a biotechnology company developing gene therapies for chronic pain and precision pain management. The company's core technology platform harnesses zinc-finger and CRISPR-based epigenome regulation to enable next-generation AAV gene therapies. The lead product is NT-Z001, a gene therapy targeting the SCN9A gene/NaV1.7 sodium channel for treatment of intractable chronic pain. The company operates from Jlabs San Diego and is funded by a $4 million CIRM Translational Science grant for preclinical development.

Product and service1 record
1NT-Z001
CategoryGene Therapy
Description

NT-Z001 is a preclinical AAV-based gene therapy candidate that targets the SCN9A gene encoding the NaV1.7 sodium channel involved in pain transmission. It is being developed for the treatment of intractable chronic pain as a non-opioid, single-administration therapeutic, intended for patients whose pain is unresponsive to conventional analgesics.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Shape Therapeutics is an RNA and gene therapy company developing epigenome-based editing platforms delivered via AAV, with programs in CNS and ophthalmology. Highly comparable to Navega in modality (AAV-delivered epigenome regulation), therapeutic focus, and platform architecture.

TypeDirect peer
Description

Chroma Medicine is developing a single-dose epigenetic editing platform to treat serious diseases, including CNS and ophthalmic indications. Directly comparable to Navega in epigenetic editing modality, target class, and gene therapy delivery approach.

TypeDirect peer
Description

Sangamo is the pioneer of zinc-finger-based genome engineering and has developed zinc-finger protein transcription factors for CNS and rare disease indications. Closely comparable to Navega on the zinc-finger protein platform technology and CNS therapeutic focus.

TypeDirect peer
Description

Voyager Therapeutics is a clinical-stage AAV gene therapy company developing CNS-targeted therapies for neurological diseases, including programs in pain and neurodegeneration. Comparable to Navega in AAV platform, CNS indication focus, and gene therapy modality.

TypeDirect peer
Description

Taysha is a clinical-stage gene therapy company focused on AAV-delivered therapies for CNS and rare neurological diseases. Comparable to Navega in AAV gene therapy modality, CNS indication focus, and pipeline development stage.

TypeEmerging player
Description

AviadoBio is an early-stage AAV gene therapy company developing treatments for neurodegenerative diseases including frontotemporal dementia and ALS. Comparable to Navega as a small, AAV-based, CNS-focused emerging gene therapy developer.

TypeEmerging player
Description

Kriya Therapeutics is a gene therapy company developing AAV-based therapies across multiple therapeutic areas including CNS and chronic pain. Comparable to Navega in AAV gene therapy platform and overlap in pain and CNS indications.

TypeDirect peer
Description

Lexicon developed small-molecule NaV1.7 inhibitors (LX9211) for chronic pain, validating the SCN9A/NaV1.7 target therapeutically. Comparable to Navega as a peer pursuing the same pain target via a different modality, providing useful reference for translational risk.

TypeBroad incumbent
Description

uniQure is a commercial-stage AAV gene therapy company with approved therapies and a broad pipeline including CNS programs. Comparable to Navega as a broader AAV gene therapy developer with greater scale, manufacturing capabilities, and clinical maturity.

TypeBroad incumbent
Description

Regenxbio is a leading AAV gene therapy platform company with multiple approved and clinical-stage CNS, ophthalmology, and rare disease programs. Comparable to Navega as a broader AAV platform incumbent with deeper capital, manufacturing, and clinical capabilities.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Navega Therapeutics

Gene Therapynavegatx.com

Navega Therapeutics is a preclinical San Diego biotech developing AAV gene therapies that use zinc-finger and CRISPR-based epigenome regulation to treat intractable chronic pain, with lead candidate NT-Z001 targeting the SCN9A/NaV1.7 sodium channel pathway.

What Navega Therapeutics does

Navega Therapeutics is a preclinical-stage biotechnology company developing next-generation AAV gene therapies that use zinc-finger and CRISPR-based epigenome regulation to precisely control gene expression without permanently editing DNA. The company's lead candidate, NT-Z001, is an AAV gene therapy targeting the SCN9A gene encoding the NaV1.7 sodium channel, a well-validated pathway in pain transmission, with the goal of treating intractable chronic pain as a non-opioid, long-lasting alternative to existing therapies. The platform is described as broadly applicable to neurological and ophthalmic diseases, positioning NT-Z001 as the first of a potentially broader pipeline.

The company operates from JLABS San Diego (3210 Merryfield Row, San Diego, CA), a Johnson & Johnson biotech incubator, with a 1–10 person team led by founder and CEO Ana Moreno and co-founder, President and CSO Fernando Aleman, supported by CBO Carol Greve-Philips. Navega is privately held, founded in 2018, and has been funded entirely through non-dilutive federal grants rather than venture capital — receiving approximately $11.85 million cumulatively from the National Cancer Institute, the National Institute of Neurological Disorders and Stroke, and the California Institute for Regenerative Medicine (CIRM), including a $4 million Translational Science grant awarded in February 2025.

The business model is pre-commercial: Navega has no products on market, no pricing structure, and no paying customers. Revenue mechanics are entirely grant-based at present, with future value expected to derive from out-licensing, partnership, or commercialization of gene-therapy assets following regulatory approval. Distribution would occur via clinical-trial sites and specialty healthcare channels post-approval. Go-to-market is therefore not yet defined, and the company's near-term milestones are scientific and regulatory (preclinical → IND-enabling → clinical) rather than commercial.

Navega Therapeutics firmographics

Firmographics
Name
Navega Therapeutics
Legal name
Navega Therapeutics
Website
https://navegatx.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Navega Therapeutics is a preclinical San Diego biotech developing AAV gene therapies that use zinc-finger and CRISPR-based epigenome regulation to treat intractable chronic pain, with lead candidate NT-Z001 targeting the SCN9A/NaV1.7 sodium channel pathway.
Ownership category
akta.pro rank

Navega Therapeutics industry classification

Industry
Product category
Gene Therapy
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAD
Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Gene therapy development
  • Epigenetic therapeutics
  • Chronic pain treatment
  • AAV gene therapy
  • Neurological disease therapy

Where Navega Therapeutics is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Navega Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Pre-commercial / Pipeline Stage: Company is in preclinical development stage with no commercial products. Future revenue expected from gene therapy product commercialization, licensing deals, and potential partnership structures typical of biotech development pipelines.

Marketing channels1 record

Navega Therapeutics product offering

Product offering

Core offering

Navega Therapeutics is a preclinical-stage biotechnology company developing next-generation AAV gene therapies for neurological and ophthalmic diseases by harnessing zinc-finger and CRISPR-based epigenome regulation to control gene expression. Its lead candidate NT-Z001 targets the SCN9A gene encoding the NaV1.7 sodium channel to treat intractable chronic pain as a potential non-opioid alternative.

Product overview

Navega Therapeutics is a biotechnology company developing gene therapies for chronic pain and precision pain management. The company's core technology platform harnesses zinc-finger and CRISPR-based epigenome regulation to enable next-generation AAV gene therapies. The lead product is NT-Z001, a gene therapy targeting the SCN9A gene/NaV1.7 sodium channel for treatment of intractable chronic pain. The company operates from Jlabs San Diego and is funded by a $4 million CIRM Translational Science grant for preclinical development.

Differentiator

Problem solved

Functional benefit

Products and services

  • NT-Z001 NT-Z001 is a preclinical AAV-based gene therapy candidate that targets the SCN9A gene encoding the NaV1.7 sodium channel involved in pain transmission. It is being developed for the treatment of intractable chronic pain as a non-opioid, single-administration therapeutic, intended for patients whose pain is unresponsive to conventional analgesics.

Companies that use Navega Therapeutics

Customer profile

Segments1 record

Ideal customer profiles2 records

Navega Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Navega Therapeutics partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Navega Therapeutics competitors and assessment

Company assessment

Direct peers

  • Shape Therapeutics: Shape Therapeutics is an RNA and gene therapy company developing epigenome-based editing platforms delivered via AAV, with programs in CNS and ophthalmology. Highly comparable to Navega in modality (AAV-delivered epigenome regulation), therapeutic focus, and platform architecture.
  • Chroma Medicine: Chroma Medicine is developing a single-dose epigenetic editing platform to treat serious diseases, including CNS and ophthalmic indications. Directly comparable to Navega in epigenetic editing modality, target class, and gene therapy delivery approach.
  • Sangamo Therapeutics: Sangamo is the pioneer of zinc-finger-based genome engineering and has developed zinc-finger protein transcription factors for CNS and rare disease indications. Closely comparable to Navega on the zinc-finger protein platform technology and CNS therapeutic focus.
  • Voyager Therapeutics: Voyager Therapeutics is a clinical-stage AAV gene therapy company developing CNS-targeted therapies for neurological diseases, including programs in pain and neurodegeneration. Comparable to Navega in AAV platform, CNS indication focus, and gene therapy modality.
  • Taysha Gene Therapies: Taysha is a clinical-stage gene therapy company focused on AAV-delivered therapies for CNS and rare neurological diseases. Comparable to Navega in AAV gene therapy modality, CNS indication focus, and pipeline development stage.
  • Lexicon Pharmaceuticals: Lexicon developed small-molecule NaV1.7 inhibitors (LX9211) for chronic pain, validating the SCN9A/NaV1.7 target therapeutically. Comparable to Navega as a peer pursuing the same pain target via a different modality, providing useful reference for translational risk.

Emerging players

  • AviadoBio: AviadoBio is an early-stage AAV gene therapy company developing treatments for neurodegenerative diseases including frontotemporal dementia and ALS. Comparable to Navega as a small, AAV-based, CNS-focused emerging gene therapy developer.
  • Kriya Therapeutics: Kriya Therapeutics is a gene therapy company developing AAV-based therapies across multiple therapeutic areas including CNS and chronic pain. Comparable to Navega in AAV gene therapy platform and overlap in pain and CNS indications.

Broad incumbents

  • uniQure: uniQure is a commercial-stage AAV gene therapy company with approved therapies and a broad pipeline including CNS programs. Comparable to Navega as a broader AAV gene therapy developer with greater scale, manufacturing capabilities, and clinical maturity.
  • Regenxbio: Regenxbio is a leading AAV gene therapy platform company with multiple approved and clinical-stage CNS, ophthalmology, and rare disease programs. Comparable to Navega as a broader AAV platform incumbent with deeper capital, manufacturing, and clinical capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

Navega Therapeutics social profiles

Digital presence

Navega Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Navega Therapeutics leadership team

Management profile

Number of profiles

Profiles3 records

Navega Therapeutics funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Navega Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Navega Therapeutics

What does Navega Therapeutics do?

Navega Therapeutics is a preclinical-stage biotechnology company developing next-generation AAV gene therapies for neurological and ophthalmic diseases by harnessing zinc-finger and CRISPR-based epigenome regulation to control gene expression. Its lead candidate NT-Z001 targets the SCN9A gene encoding the NaV1.7 sodium channel to treat intractable chronic pain as a potential non-opioid alternative.

Is Navega Therapeutics a public or private company?

Navega Therapeutics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Navega Therapeutics founded?

Navega Therapeutics was founded in 2018. It employs 11 to 50 people.

Where is Navega Therapeutics based?

Navega Therapeutics is headquartered in San Diego, United States, in the North America region.

How does Navega Therapeutics make money?

One revenue line is on record: pre-commercial / Pipeline Stage.

Who are Navega Therapeutics's main competitors?

Direct peers on record are Shape Therapeutics, Chroma Medicine, Sangamo Therapeutics, Voyager Therapeutics, Taysha Gene Therapies and Lexicon Pharmaceuticals. Emerging players are AviadoBio and Kriya Therapeutics. Broad incumbents are uniQure and Regenxbio.

Does Navega Therapeutics have an API?

No public API is recorded for Navega Therapeutics.

What industry is Navega Therapeutics in?

Navega Therapeutics's product category is Gene Therapy. Its primary akta.pro industry code is HLAAACAH, Neurology/CNS Gene Therapies, with a secondary code of HLAAACAA, AAV Vector Gene Therapy Developers. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireNavega Therapeutics Announces CIRM Grant for Treatment of Chronic PainNavega Therapeutics received a $4M CIRM grant for preclinical development of NT-Z001, an epigenetic gene therapy targeting NaV1.7 to treat chronic pain. The grant supports final preclinical studies leading to an IND. The company's second CIRM grant follows.YahooNavega Therapeutics Announces CIRM Grant for Treatment of Chronic PainNavega Therapeutics, a San Diego-based biotechnology company, announced receipt of a $4M Translational Science grant from CIRM to advance its AAV gene therapy candidate NT-Z001, a non-opioid treatment targeting chronic neuropathic pain by down-regulating the NaV1.7 sodium channel via epigenetic editing. The grant will fund final preclinical development studies required to file an Investigational New Drug application with the FDA. The funding follows a prior CIRM grant supporting NT-Z001's development and reflects continued institutional confidence in the company's AI-enabled zinc-finger epigenome regulation platform for treating intractable pain conditions.PR NewswireNAVEGA THERAPEUTICS APPOINTS CAROL GREVE-PHILIPS CHIEF BUSINESS OFFICERNavega Therapeutics, a privately-held early-stage pharmaceutical company based in San Diego, has appointed Carol Greve-Philips as Chief Business Officer to lead business development and pursue commercialization agreements for its lead program NT-Z001. Greve-Philips brings 35 years of deal-making experience in rare disease and gene therapy, with a portfolio that includes transactions for Genzyme, Spark Therapeutics, Quad Technologies, and AbFero. The appointment follows strong preclinical data and advances the company's transition from proof-of-concept toward clinical-stage development with support from NIH and CIRM.PR NewswireNavega Therapeutics expands its Scientific Advisory Board with the addition of pain expert, Dr. Stephen Waxman.Navega Therapeutics, a San Diego-based preclinical biotechnology company developing epigenetic gene therapies for chronic pain, announced the expansion of its Scientific Advisory Board with the addition of Dr. Stephen Waxman from Yale University. Dr. Waxman, a renowned pain researcher credited with identifying the role of ion channels and NaV1.7 mutations in inherited pain disorders like Inherited Erythromelalgia, brings over 700 publications and an H-index of 109 to the advisory board. The company stated it will leverage Dr. Waxman's expertise as it advances toward IND-enabling studies for its DNA-targeting approach to treating chronic pain, which affects 1.5 billion people worldwide with an estimated economic burden of $560 billion.BioWorldStartup Navega tests gene therapy for pain syndromesResearchers at the University of California at San Diego used gene therapy to suppress the Nav 1.7 ion channel in the spinal cord, treating pain in several animal models. The approach both prevented and reversed pain in models with distinct underlying causes.UC San Diego TodayWith Gene Therapy, Scientists Develop Opioid-Free Solution for Chronic PainResearchers at UC San Diego developed a gene therapy that temporarily represses the Na V 1.7 gene, increasing pain tolerance in mice for months without causing numbness. The therapy, published in Science Translational Medicine, could treat chronic pain conditions like diabetic neuropathy and osteoarthritis. The team plans to optimize the approach and begin human clinical trials in a couple of years.News-MedicalUsing CRISPR to switch off pain gene becomes a possibility with new studyScientists used CRISPR to edit epigenetic markers regulating the SCN9A pain gene, reducing pain in mice across three models. The effect is reversible and tunable, with no addiction risk, and human trials are planned from next year. Approval could take five years.Mail OnlineHope for millions as scientists learn how to 'edit out' PAINScientists at Navega Therapeutics discovered a CRISPR-based technique to silence the pain gene SCN9A, reducing pain signals in mice. The treatment, expected to be available in five years, could help cancer patients tolerate chemotherapy without opioids. Human trials are planned next year.MIT Technology ReviewThe next trick for CRISPR is gene-editing pain awayScientists used CRISPR to temporarily block pain signals in mice, mimicking a rare mutation that causes no pain. The approach could treat chronic pain from diabetes, cancer, or accidents without opioid addiction. A startup plans to develop a CRISPR pain treatment, with human trials expected soon.KpbsThe Next Big Idea: On The Ground Floor Of A Potential Biotech GiantAna Maria Moreno, co-founder and CEO of Navega Therapeutics, is developing a patented therapy to reduce pain sensitivity without pain-relieving drugs. The company is seeking $2 million to fund pre-clinical trials. Moreno cites her family's entrepreneurial background as motivation.